Journal article
Threat of Sexual Disqualification: The Consequences of Erectile Dysfunction and Other Sexual Changes for Gay and Bisexual Men With Prostate Cancer
JM Ussher, J Perz, D Rose, GW Dowsett, S Chambers, S Williams, I Davis, D Latini
Archives of Sexual Behavior | SPRINGER/PLENUM PUBLISHERS | Published : 2017
Open access
Abstract
Gay and bisexual (GB) men with prostate cancer (PCa) have been described as an “invisible diversity” in PCa research due to their lack of visibility, and absence of identification of their needs. This study examined the meaning and consequences of erectile dysfunction (ED) and other sexual changes in 124 GB men with PCa and 21 male partners, through an on-line survey. A sub-sample of 46 men with PCa and seven partners also took part in a one-to-one interview. ED was reported by 72 % of survey respondents, associated with reports of emotional distress, negative impact on gay identities, and feelings of sexual disqualification. Other sexual concerns included loss of libido, climacturia, loss o..
View full abstractGrants
Awarded by Prostate Cancer Foundation of Australia
Funding Acknowledgements
This study was funded by Prostate Cancer Foundation of Australia (PCFA), in the form of a new concept grant NCG0512, in partnership with ANZUP (Australian and New Zealand Urogenital and Prostate Cancer Trials Group). The investigators on the project were Jane Ussher (PI), Janette Perz (CI), Suzanne Chambers (CI), David Latini (CI), Ian Davis (AI), Scott Williams(AI), Gary Dowsett (AI), and Alan Brotherton (AI). Duncan Rose was employed as the research officer. Thanks are offered to Samantha Murray, Mo Hammond, Margaret McJannet, Greg Millan, PCFA, The Sax 45 and Up Study, NBCF Register 4, Cancer Council NSW, ACON, and Male Care for recruitment of participants, and to Chloe Parton and Andrew Kellett for research assistance and support. Finally, we thank all of the men with prostate cancer who completed the survey and took part in interviews to share their personal stories of sexual well-being after prostate cancer with us.